Phase: I

A First-in-Human Open-Label Phase 1/2a Study to Evaluate Safety, Tolerability and Efficacy of a Single Intra-Articular Injection of Allogeneic Mesenchymal Stem Cells Selected for Integrin α10β1 (XSTEM-OA) in Adult Patients with Symptomatic Knee Osteoarthritis.

Year: 2023
Type: Musculoskeletal
Phase: First-in-Human, I, IIa
Indication: Knee Osteoarthritis

A Phase I/IIa, Multicenter, Open-label, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration.

Year: 2013
Type: Pharmaceutical - Pain
Phase: I, IIa
Indication: Back and/or Leg Pain

CONNECT WITH US

CONTACT US

Disclaimer: This website provides general information only; it should not be construed as medical advice nor does it replace the need to seek medical advice from a qualified medical professional. To the maximum extent permitted by law, Genesis Research Services Pty Ltd will not be liable in any way for any injury, loss or damage suffered by you through accessing or using the information on this website. View our Privacy Policy. You are strictly prohibited from downloading, copying, altering, modifying, distributing, adapting, modifying and/or re-transmitting any or all of the content on the website for any commercial use without the written consent of Genesis Research Services.